Stoke Therapeutics (STOK) Posted Mixed Q3 Results, Is The Stock Still Undervalued?

Stoke Therapeutics (STOK) just delivered third quarter 2026 results that paired higher reported sales with a much wider loss, giving investors fresh numbers to reassess this clinical stage biotech stock.

At a share price of US$26.35, Stoke Therapeutics has seen a 2.5% 7 day share price gain but remains down 14.7% year to date, while the 1 year total shareholder return has declined 16.9% after an earlier 3 year total shareholder return that is more than 5x. Recent interest has been driven by the Q3 revenue and loss update alongside progress in the Phase 3 EMPEROR program for zorevunersen and the ongoing Phase 1 work on STK-002. The mixed returns suggest that momentum has cooled compared with recent years as investors weigh trial milestones against a wider loss profile.

Scan for other clinical-stage stories with similar risk and reward profiles by reviewing the hand-picked 18 high quality undiscovered gems that may be flying under most investors radar.

Stoke Therapeutics now trades well below the average analyst valuation, yet the stock just bounced on mixed Q3 numbers. Is this a genuine discount, or a price that already reflects the clinical risk?

Most Popular Narrative: 42% Undervalued

On Simply Wall St's most followed narrative, Stoke Therapeutics screens as materially undervalued, with a fair value of $45.10 against the last close at $26.35. This puts a spotlight on whether the Q3 selloff has gone too far for a clinical stage biotech that is still loss making.

Increasing complexity and cost of global late-stage programs in neurology, including sham-controlled intrathecal studies and country-specific regulatory demands, is likely to drive continued operating expense growth faster than topline collaboration revenue. This could pressure operating margins and earnings.

See why 6 investors see Stoke Therapeutics as 42% undervalued.

Result: Fair Value of $45.10 (UNDERVALUED)

Still, the story for Stoke Therapeutics can shift quickly if the EMPEROR Phase 3 trial underwhelms or if regulators demand longer and more expensive paths to approval.

Find out about the key risks to this Stoke Therapeutics narrative.

Another View: Stoke Therapeutics Through A P/B Lens

On a simple P/B check, Stoke Therapeutics screens as expensive versus the broader US Biotechs group, with a 4.9x ratio against a 2x sector average. Against closer peers on 49.2x, though, that same multiple looks far lower. Which crowd should an investor pay more attention to?

To pressure test that P/B signal against detailed fundamentals and peer sets, it helps to step back and see what the numbers say in a structured valuation breakdown, including where the fair ratio might sit if sentiment shifts toward the sector norm. Then cross check that with the See what the numbers say about this price — find out in our valuation breakdown..

For a visual read on how Stoke Therapeutics stacks up against the biotech pack on this metric, review the latest relative valuation snapshot here

.

Next Steps

Sentiment on Stoke Therapeutics is mixed, with strong upside arguments set against visible clinical and financial risks. Move fast and review the evidence for yourself, then weigh both the upside potential and the downside flags in the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Stoke Therapeutics?

If Stoke Therapeutics has your attention, do not stop here. Broaden your watchlist now and let the data surface opportunities you might otherwise miss.

• Target resilient cash generators with healthy fundamentals by scanning the list of solid balance sheet and fundamentals (23 results) that already clear strict balance sheet filters.
• Hunt for potential mispriced opportunities by reviewing the 30 high quality undervalued stocks that pair quality metrics with discounted market prices.
• Prioritise stability and capital protection by focusing on the 30 resilient stocks with low risk scores that score well on downside and volatility checks.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com